Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
· cnbc.com
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded
Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is ent...